Cobicistat
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Cobicistat |
| DrugBank ID | DB09065 |
| Brand Names (EU) | Tybost |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.95% |
Approved Indication (EMA)
Tybost is indicated as a pharmacokinetic enhancer of atazanavir 300 mg once daily or darunavir 800 mg once daily as part of antiretroviral combination therapy in human immunodeficiency virus-1 (HIV-1) infected adults and adolescents aged 12 years and older: weighing at least 35 kg co?administered with atazanavir or weighing at least 40 kg co?administered with darunavir.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | HIV infectious disease | 99.95% | DL |
| 2 | feline acquired immunodeficiency syndrome | 99.92% | DL |
| 3 | simian immunodeficiency virus infection | 99.92% | DL |
| 4 | neurodevelopmental disorder with ataxic gait, absent speech, and decreased cortical white matter | 99.91% | DL |
| 5 | AIDS | 99.21% | DL |
| 6 | chronic hepatitis C virus infection | 98.70% | DL |
| 7 | congenital human immunodeficiency virus | 98.33% | DL |
| 8 | AIDS related complex | 98.33% | DL |
| 9 | hepatitis C virus infection | 97.00% | DL |
| 10 | obsolete familial combined hyperlipidemia | 96.78% | DL |
| 11 | hepatitis B virus infection | 96.49% | DL |
| 12 | hepatitis E virus infection | 96.16% | DL |
| 13 | hepatitis A virus infection | 96.06% | DL |
| 14 | Omsk hemorrhagic fever | 96.00% | DL |
| 15 | hepatitis, viral, animal | 95.97% | DL |
| 16 | Kyasanur forest disease | 95.89% | DL |
| 17 | fibroma of prostate | 92.72% | DL |
| 18 | Brenner tumor | 92.43% | DL |
| 19 | benign reproductive system neoplasm | 92.37% | DL |
| 20 | benign prostate phyllodes tumor | 91.98% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.